Molecular Cytogenetics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Molecular Cytogenetics Market is segmented By Product (Kits and Reagents, Instruments, Consumables, Software & Services), By Technique (Comparative Genomic Hybridization, Fluorescence in Situ Hybridization, Karyotyping, Others), By Application (Genetic Disorders, Oncology, Targeted Drug Therapy, Others), By End User (Clinical & Research Laboratories, Academic Research Institutes, Hospitals & Pathology Laboratories, Pharmaceutical, and Biotechnology Companies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031 

Molecular Cytogenetics Market Overview

150 Pages report analyses the molecular cytogenetics market shares, size, recent trends, future market outlook, and competitive intelligence. Molecular cytogenetics usage in genetic disorders and oncology is on the rise. Demand from clinical & research laboratories and academic research institutes in the USA is rising. The competitive rivalry intensifies with Oxford Gene Technology, Bio-Rad Laboratories, and others active in the market.

Molecular cytogenetics is the study of chromosomes. Molecular cytogenetics helps in disease pathogenesis, 3D organization of the human genome, the nature of inherited syndromes, and genetic anomalies such as cancer, sickle cell anemia, cystic fibrosis, Down’s syndrome, and others. Cytogenetics is an important technique for the development of targeted cancer treatment. Molecular Cytogenetics consists of a wide range of techniques such as comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), and karyotyping. Due to continuous technological advancements in cytogenetics and, mapping techniques of the human genome, researchers can look into the disease-causing mechanism at a genomic as well as cellular level as well get insights about the transmittance of diseases from child to parents.

Molecular Cytogenetics Market Summary

To Get a Free Sample Click here

Molecular Cytogenetics Market Dynamics

The market is driven by a high incidence of genetic disorders and cancer, a growing focus on targeted cancer treatment, an increase in the geriatric population, and technological advancements.

The continuous rise in cancer cases globally is boosting the need for targeted cancer treatment and the development of advanced technologies for the identification and treatment of cancer at the genomic level. According to Cancer Research UK, there were 17 million new cases of cancer worldwide in 2018 and 9.6 million deaths. FISH and CGH are recognized cytogenetic techniques that provide information about cancer-related molecular signatures — these methods aid in gaining insights into cancer progression.

The high cost of advanced instruments, unfavorable reimbursement scenario, lack of skilled persons to handle genomic tools, and high expense associated with maintenance and handling of advanced techniques are going to restrain the market in the forecast period.

Molecular Cytogenetics Market Segmentation Analysis

The global molecular cytogenetics market can be segmented by product as Kits and Reagents, Instruments, Consumables, and Software & Services, by technique Comparative Genomic Hybridization, Fluorescence in Situ Hybridization (FISH), Karyotyping and Others, by applications such as Genetic Disorders, Oncology, Targeted Drug Therapy, and Others and by end-user as Clinical & Research Laboratories, Academic Research Institutes, Hospitals & Pathology Laboratories, Pharmaceutical, and Biotechnology Companies and Others.

FISH is expected to account for the largest market share throughout the forecast. FISH is a powerful diagnostic and discovery tool for identifying the genomic status of oncology tissues. FISH involves the use of fluorescence probes to detect specific gene sequences within chromosomes and can be used to detect different kinds of mutations such as gene amplification, deletions, and translocations. Even viral sequences can be detected. FISH has greatly expanded the capabilities of cytogenetics and pathology laboratories through its high sensitivity, specificity, and rapid turnover with high efficiency of hybridization and detection. FISH material can be processed in 4–24h, and the analysis of 1000–2000 cells is accomplished in 15–45 min, enabling the information on the cytogenetic pattern of tumor cells to be achieved within a sufficient time frame for use in treatment strategies.

Molecular Cytogenetics Market Geographical Share

Geographically, the global molecular cytogenetics market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North America is expected to hold the largest market share in the period forecast, due to a rise in cancer and other genetic diseases. The rise in the geriatric population also plays a major role in driving the North American market. Mental retardation can also be diagnosed and treated at the molecular level with the help of cytogenetic analysis. Mental retardation (MR) affects more than 300,000 Canadians with a life-long severe disability. The cause of most mental retardation remains unknown, but abnormalities of the chromosomes, and the packages of genes within cells, are the most frequently recognized cause. Children with MR of unknown cause may be subjected to repeated medical testing to determine the cause, and their families often find it difficult to obtain appropriate educational or social support. The Canadian Molecular Cytogenetics Platform is an infrastructural partnership of 13 major research facilities. The platform includes a system for the collection of clinical research data and specimens from 18 centers in 7 provinces.

Molecular Cytogenetics Market Companies and Competitive Landscape

• Some of the major key players in the market are Applied Spectral Imaging, Oxford Gene Technology, Bio-Rad Laboratories, Illumina, Inc., PerkinElmer, Inc., Agilent Technologies, Abbott Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., MetaSystems, and Quest Diagnostics Incorporated.
• In February 2019, Bio-Rad Laboratories, Inc. announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit is the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance.
• In January 2019, Applied Spectral Imaging launched a new product update to facilitate the growing demands of pathology and cytogenetic laboratories. The product update includes a novel imaging methodology based on an all-new algorithm coupled with advanced hardware components to increase the scanning speed for FISH imaging.
• In January 2019, Oxford Gene Technology has been granted de novo classification by the US FDA for eight Cytocell Aquarius® Hematology FISH probes for acute myeloid leukemia and myelodysplastic syndromes.
• In December 2018, Illumina, Inc. announced the launch of its new high-density genotyping array, the Infinium™ Global Diversity Array. The acquisition complements Illumina sequencing solutions with accurate long-read sequencing capabilities to answer a set of complex genomic questions
• In November 2018, Illumina, Inc. acquired Pacific Biosciences for $8.00 per Pacific Biosciences share in an all-cash transaction.
• In August 2018, Oxford Gene Technology announced the launch of the eagerly-anticipated update to its SureSeq™ Interpret software, included with purchases of SureSeq NGS panels.